3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
220
Neoplasms
192
Carcinoma, Non-Small-Cell Lung
185
Colorectal Neoplasms
129
Prostatic Neoplasms
119
Lung Neoplasms
107
Neoplasm Metastasis
91
Multiple Myeloma
89
Ovarian Neoplasms
85
Pancreatic Neoplasms
78
Squamous Cell Carcinoma of Head and Neck
71
Leukemia, Myeloid, Acute
70
Melanoma
61
Stomach Neoplasms
56
Recurrence
51
Endometrial Neoplasms
50
Brain Neoplasms
46
Lymphoma
45
Carcinoma, Renal Cell
45
Carcinoma, Hepatocellular
45
Glioblastoma
44
Urinary Bladder Neoplasms
43
Triple Negative Breast Neoplasms
43
Precursor Cell Lymphoblastic Leukemia-Lymphoma
42
Hematologic Neoplasms
40
Esophageal Neoplasms
39
Lymphoma, Large B-Cell, Diffuse
37
Leukemia, Lymphocytic, Chronic, B-Cell
37
Head and Neck Neoplasms
37
Lymphoma, Non-Hodgkin
36
Interventions
Alpelisib
2
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphatic Abnormalities
×
30 days
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled